A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.
Elevated peak donor troponin levels are associated with an increased risk for 1-year graft loss in pediatric heart transplant recipients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results